{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:08:27Z","timestamp":1793858907670,"version":"4.6.1"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pompe disease, a rare autosomal recessive metabolic myopathy, is primarily treated with enzyme replacement therapy (ERT); however, ERT response depends on several factors, including ERT initiation age, dose, and cross-reactive immunological material (CRIM) status, especially in infantile-onset Pompe disease (IOPD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This systematic literature review (SLR) focused on three research questions (1): how CRIM status is determined in patients with IOPD in clinical practice, and how CRIM-negative status impacts outcomes (2); how health professionals use CRIM status to inform their decisions on immune tolerance induction (ITI) regimens; and (3) which regimens are used in real-world clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The SLR was conducted using Embase and PubMed databases covering the literature from January 1, 2003, to August 4, 2022. The search terms used were \u201cPompe or IOPD\u201d and \u201ccross-reactive immunological material or CRIM.\u201d Data extraction was performed using pre-designed tables in Microsoft Excel. Among those identified, 54, 51, and 69 studies provided meaningful data for the respective research questions. The key theme was the importance of early diagnosis\/treatment. Recently, there has been a major shift from direct CRIM testing using western blotting and mutation analysis to CRIM status prediction based on genetic variant analysis. The ITI regimen was mostly prescribed for CRIM-negative patients and some CRIM-positive cases in a prophylactic\/na\u00efve setting at ERT initiation to prevent the development of high antibodies and for IOPD patients irrespective of CRIM status in the ERT-experienced setting due to the presence of high and sustained anti-drug antibody levels. The frequently reported ITI regimen includes a short rituximab and methotrexate course in an ERT na\u00efve setting, with\/without intravenous immunoglobulin. CRIM-negative patients receiving ITI with ERT have better clinical outcomes than those not receiving the ITI regimen. Presently, the ITI regimen used in CRIM-positive patients is variable and based on physician preference, family history, or specific variants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study concluded that CRIM status determination is important in patients with IOPD and impacts management approaches. ITI use has been predominantly reported in CRIM-negative patients to improve the clinical outcomes, with other important factors being early initiation of ERT and treatment above label dose of alglucosidase alpha and many are doing upto 40 mg\/kg\/2 weeks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1690312","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:12:23Z","timestamp":1767849143000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Insights into immunogenicity and therapeutic strategies to mitigate the immune response in infantile-onset Pompe disease: a comprehensive systematic literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Priya S.","family":"Kishnani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna M. P.","family":"Van Den Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kronn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Hsiu","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Heuterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Glen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Daba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.18632\/aging.103794","article-title":"Pompe disease: pathogenesis, molecular genetics and diagnosis","volume":"12","author":"Taverna","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1221140","article-title":"An analysis of Pompe newborn screening data: a new prevalence at birth, insight and discussion","volume":"11","author":"Colburn","year":"2023","journal-title":"Front Pediatr"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"B5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s13023-022-02545-w","article-title":"Expert Group Consensus on early diagnosis and management of infantile-onset pompe disease in the Gulf Region","volume":"17","author":"Al-Hassnan","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-0655-y","article-title":"Pompe disease: from basic science to therapy","volume":"15","author":"Kohler","year":"2018","journal-title":"Neurotherapeutics"},{"key":"B8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.21037\/atm.2019.04.70","article-title":"Long-term outcome and unmet needs in infantile-onset Pompe disease","volume":"7","author":"Hahn","year":"2019","journal-title":"Ann Transl Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"108559","DOI":"10.1016\/j.ymgme.2024.108559","article-title":"Clinical insight meets scientific innovation to develop a next generation ERT for Pompe disease","volume":"143","author":"Kishnani","year":"2024","journal-title":"Mol Genet Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2024.108590","article-title":"Pompe disease: Unmet needs and emerging therapies","volume":"143","author":"George","year":"2024","journal-title":"Mol Genet Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s13023-023-02981-2","article-title":"Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry","volume":"18","author":"Kishnani","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.0552","article-title":"Efficacy and safety of avalglucosidase alfa in patients with late-onset pompe disease after 97 weeks: A phase 3 randomized clinical trial","volume":"80","author":"Kishnani","year":"2023","journal-title":"JAMA Neurol"},{"key":"B13","unstructured":"Nexviadyme\u00ae (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease\n          \n          \n          \n          2022"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e15286","DOI":"10.1111\/ped.15286","article-title":"The earliest enzyme replacement for infantile-onset Pompe disease in Japan","volume":"64","author":"Tocan","year":"2022","journal-title":"Pediatr Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2024.101163","article-title":"Efficacy and safety of avalglucosidase alfa in Japanese patients with late-onset and infantile-onset Pompe diseases: A case series from clinical trials","volume":"42","author":"Mori-Yoshimura","year":"2025","journal-title":"Mol Genet Metab Rep"},{"key":"B16","unstructured":"New Phase 3 data presented at WORLDSymposium\u2122 reinforce Nexviazyme\u00ae (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01886-5","article-title":"Cipaglucosidase alfa: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1542\/peds.113.5.e448","article-title":"Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk","volume":"113","author":"Van den Hout","year":"2004","journal-title":"Pediatrics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/s2352-4642(21)00308-4","article-title":"Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium","volume":"6","author":"Ditters","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2020.100591","article-title":"Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences","volume":"23","author":"Chien","year":"2020","journal-title":"Mol Genet Metab Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.xphs.2019.05.031","article-title":"Considerations for the design of antibody-based therapeutics","volume":"109","author":"Goulet","year":"2020","journal-title":"J Pharm Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2174\/1389203718666170828123449","article-title":"Immunogenicity in protein and peptide based-therapeutics: an overview","volume":"19","author":"Fernandez","year":"2018","journal-title":"Curr Protein Pept Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.clim.2019.01.009","article-title":"HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA)","volume":"200","author":"De Groot","year":"2019","journal-title":"Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alfa prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31319","article-title":"Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience","author":"Bali","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-014-9707-6","article-title":"Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease","volume":"38","author":"van Gelder","year":"2015","journal-title":"J Inherit Metab Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1336599","article-title":"Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e67052","DOI":"10.1371\/journal.pone.0067052","article-title":"Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT","volume":"8","author":"Banugaria","year":"2013","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-018-0270-7","article-title":"An immune tolerance approach using transient low-dose methotrexate in the ERT-naive setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease","volume":"21","author":"Kazi","year":"2019","journal-title":"Genet Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.21037\/atm.2019.05.27","article-title":"Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review","volume":"7","author":"Desai","year":"2019","journal-title":"Ann Transl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1360369","article-title":"An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation","volume":"15","author":"Desai","year":"2024","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01727","article-title":"Benefits of prophylactic short-course immune tolerance induction in patients with infantile pompe disease: demonstration of long-term safety and efficacy in an expanded cohort","volume":"11","author":"Desai","year":"2020","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e94328","DOI":"10.1172\/jci.insight.94328","article-title":"Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease","volume":"2","author":"Kazi","year":"2017","journal-title":"JCI Insight"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-020-01080-y","article-title":"Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction","volume":"23","author":"Li","year":"2021","journal-title":"Genet Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2012.110","article-title":"Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease","volume":"15","author":"Banugaria","year":"2013","journal-title":"Genet Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13023-019-1039-z","article-title":"Effects of immunomodulation in classic infantile Pompe patients with high antibody titers","volume":"14","author":"Poelman","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2012.01.019","article-title":"Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells","volume":"105","author":"Banugaria","year":"2012","journal-title":"Mol Genet Metab"},{"key":"B41","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jpeds.2013.03.002","article-title":"B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease","volume":"163","author":"Elder","year":"2013","journal-title":"J Pediatr"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/8904_2012_192","article-title":"CRIM-negative pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy","volume":"9","author":"Khallaf","year":"2013","journal-title":"JIMD Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2014.33","article-title":"B-cell depletion is protective against anti-AAV capsid immune response: A human subject case study","volume":"1","author":"Corti","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-013-0475-3","article-title":"Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study","volume":"126","author":"Markic","year":"2014","journal-title":"Wien Klin Wochenschr"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2014.12.037","article-title":"The UK experience of enzyme replacement therapy in patients with infantile onset Pompe disease","volume":"114","author":"Broomfield","year":"2015","journal-title":"Mol Genet Metab"},{"key":"B46","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jpeds.2014.10.068","article-title":"Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth","volume":"166","author":"Chien","year":"2015","journal-title":"J Pediatr"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.6","article-title":"CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy","volume":"17","author":"Berrier","year":"2015","journal-title":"Genet Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.ymgme.2014.12.030","article-title":"Discordant clinical responses in CRIM-positive IPD siblings demonstrate need for prophylactic ITI in the naive setting","volume":"114","author":"Sheets","year":"2015","journal-title":"Mol Genet Metab"},{"key":"B49","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jpeds.2019.08.058","article-title":"Clinical and molecular disease spectrum and outcomes in patients with infantile-onset pompe disease","volume":"216","author":"Gupta","year":"2020","journal-title":"J Pediatr"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet Med"},{"key":"B51","first-page":"81","article-title":"Enzyme replacement therapy in Pompe disease in Northern Israel - A six year follow-up","volume":"98","author":"Mandel","year":"2009","journal-title":"Mol Genet Metab"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2003-0988-L","article-title":"Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease","volume":"114","author":"Hunley","year":"2004","journal-title":"Pediatrics"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-2222","article-title":"Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program","volume":"122","author":"Chien","year":"2008","journal-title":"Pediatrics"},{"key":"B54","unstructured":"Drug approval package\n          \n          \n          \n          2006"},{"key":"B55","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.ymgme.2008.11.116","article-title":"Immune-modulation therapy in a CRIM negative Pompe disease patient blocks antibody formation towards Myozyme, reverses cardiomyopathy, and prolongs survival","volume":"96","author":"Rhead","year":"2009","journal-title":"Mol Genet Metab"},{"key":"B56","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1542\/peds.2016-0280E","article-title":"Management of confirmed newborn-screened patients with pompe disease across the disease spectrum","volume":"140","author":"Kronn","year":"2017","journal-title":"Pediatrics"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2011.08.003","article-title":"Atypical immunologic response in a patient with CRIM-negative Pompe disease","volume":"104","author":"Abbott","year":"2011","journal-title":"Mol Genet Metab"},{"key":"B58","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/8904_2017_46","article-title":"Rapidly progressive white matter involvement in early childhood: the expanding phenotype of infantile onset pompe","volume":"39","author":"Broomfield","year":"2018","journal-title":"JIMD Rep"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2020.12.044","article-title":"Early diagnosis and treatment of infantile-onset Pompe disease via newborn screen","volume":"132","author":"Cohen","year":"2021","journal-title":"Mol Genet Metab"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200587","article-title":"In utero enzyme-replacement therapy for infantile-onset pompe's disease","volume":"387","author":"Cohen","year":"2022","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-015-9898-5","article-title":"Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy","volume":"39","author":"Broomfield","year":"2016","journal-title":"J Inherit Metab Dis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2015.10.012","article-title":"Clinical laboratory experience of blood CRIM testing in infantile pompe disease","volume":"5","author":"Bali","year":"2015","journal-title":"Mol Genet Metab Rep"},{"key":"B63","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ymgme.2013.08.010","article-title":"A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease","volume":"111","author":"Wang","year":"2014","journal-title":"Mol Genet Metab"},{"key":"B64","unstructured":"Myozyme\u00ae (alglucosidase alfa). Summary of Product Characteristics"},{"key":"B65","unstructured":"Lumizyme\u00ae (alglucosidase alfa). Prescribing information\n          \n          \n          \n          2020"},{"key":"B66","unstructured":"NEXVIAZYME (avalglucosidase alfa-ngpt) for injection, for intravenous use"},{"key":"B67","unstructured":"Pompe variant database\n          \n          \n          2024"},{"key":"B68","unstructured":"Berkeley drosophila genome project"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/ijns6020030","article-title":"The timely needs for infantile onset pompe disease newborn screening-practice in Taiwan","volume":"6","author":"Chiang","year":"2020","journal-title":"Int J Neonatal Screen"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2019.100475","article-title":"Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy","volume":"20","author":"Desai","year":"2019","journal-title":"Mol Genet Metab Rep"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2022.100893","article-title":"A favorable outcome in an infantile-onset Pompe patient with cross reactive immunological material (CRIM) negative disease with high dose enzyme replacement therapy and adjusted immunomodulation","volume":"32","author":"Curelaru","year":"2022","journal-title":"Mol Genet Metab Rep"},{"key":"B72","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1016\/j.ymgme.2016.11.355","article-title":"A case study of infantile Pompe: Clinical outcomes of early treatment in the first year of life","volume":"120","author":"Vucko","year":"2017","journal-title":"Mol Genet Metab"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12268","article-title":"Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients","volume":"43","author":"Poelman","year":"2020","journal-title":"J Inherit Metab Dis"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1136\/jmg-2022-108675","article-title":"Long-term outcomes of very early treated infantile-onset Pompe disease with short-term steroid premedication: experiences from a nationwide newborn screening programme","volume":"60","author":"Yang","year":"2023","journal-title":"J Med Genet"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2015.05.004","article-title":"Immune tolerance strategies in siblings with infantile pompe disease-advantages for a preemptive approach to high-sustained antibody titers","volume":"4","author":"Stenger","year":"2015","journal-title":"Mol Genet Metab Rep"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2017.05.006","article-title":"High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient","volume":"122","author":"Rairikar","year":"2017","journal-title":"Mol Genet Metab"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2022.01.064","article-title":"eP026: Newborn screening for Pompe disease: The Indiana experience","volume":"24","author":"McPheron","year":"2022","journal-title":"Genet Med"},{"key":"B78","article-title":"Long term follow-up of patients diagnosed by Pompe Disease newborn screening","volume":"42","author":"Pascarella","year":"2019","journal-title":"J Inherited Metab Disease"},{"key":"B79","doi-asserted-by":"publisher","first-page":"S162","DOI":"10.1016\/j.nmd.2017.06.250","article-title":"Antibody formation to enzyme replacement therapy in classic infantile pompe disease: Effects of immunomodulation in naive patients","volume":"27","author":"Poelman","year":"2017","journal-title":"Neuromuscular Disord"},{"key":"B80","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jpeds.2017.11.046","article-title":"High sustained antibody titers in patients with classic infantile pompe disease following immunomodulation at start of enzyme replacement therapy","volume":"195","author":"Poelman","year":"2018","journal-title":"J Pediatr"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01929","article-title":"A race against time-changing the natural history of CRIM negative infantile pompe disease","volume":"11","author":"Gupta","year":"2020","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.14070","article-title":"Infantile-onset Pompe disease: A case series highlighting early clinical features, spectrum of disease severity and treatment response","volume":"54","author":"Owens","year":"2018","journal-title":"J Paediatr Child Health"},{"key":"B83","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.clinthera.2011.05.058","article-title":"Treatment outcome of pompe disease infants with negative cross-reactive immunologic material from Israel and gaza","volume":"33","author":"Mandel","year":"2011","journal-title":"Clin Ther"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.33588\/rn.6306.2016232","article-title":"Clinical guidelines for infantile-onset Pompe disease","volume":"63","author":"Pascual-Pascual","year":"2016","journal-title":"Rev Neurol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13052-022-01219-4","article-title":"Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel","volume":"48","author":"Gragnaniello","year":"2022","journal-title":"Ital J Pediatr"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2000.107112","article-title":"Identification of two subtypes of infantile acid Maltase deficiency","volume":"137","author":"Slonim","year":"2000","journal-title":"J Pediatr"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2010.08.009","article-title":"High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa","volume":"101","author":"de Vries","year":"2010","journal-title":"Mol Genet Metab"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636731","article-title":"Immune tolerance-adjusted personalized immunogenicity prediction for pompe disease","volume":"12","author":"De Groot","year":"2021","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2022.100929","article-title":"Newborn screening for Pompe disease in Italy: Long-term results and future challenges","volume":"33","author":"Gragnaniello","year":"2022","journal-title":"Mol Genet Metab Rep"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10526-5","article-title":"Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis","volume":"269","author":"Sarah","year":"2022","journal-title":"J Neurol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3390\/children8111026","article-title":"Importance of timely treatment initiation in infantile-onset pompe disease, a single-centre experience","volume":"8","author":"de Las Heras","year":"2021","journal-title":"Children (Basel)"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1301912","article-title":"Immunophenotype associated with high sustained antibody titers against enzyme replacement therapy in infantile-onset Pompe disease","volume":"14","author":"Desai","year":"2023","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2023.100981","article-title":"Development of high sustained anti-drug antibody titers and corresponding clinical decline in a late-onset Pompe disease patient after 11+ years on enzyme replacement therapy","volume":"36","author":"Kim","year":"2023","journal-title":"Mol Genet Metab Rep"},{"key":"B95","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/s10545-012-9512-z","article-title":"Abstracts of the annual symposium of the society for the study of inborn errors of metabolism. Birmingham, United Kingdom. September 4-7, 2012","author":"Hasano\u011flu","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.86821","article-title":"Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses","volume":"1","author":"Kazi","year":"2016","journal-title":"JCI Insight"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1690312\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:12:29Z","timestamp":1767849149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1690312\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":96,"alternative-id":["10.3389\/fimmu.2025.1690312"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1690312","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"article-number":"1690312"}}